DK0633893T3 - 17-Substituerede steroider, der er nyttige ved cancerbehandling - Google Patents

17-Substituerede steroider, der er nyttige ved cancerbehandling

Info

Publication number
DK0633893T3
DK0633893T3 DK93906670T DK93906670T DK0633893T3 DK 0633893 T3 DK0633893 T3 DK 0633893T3 DK 93906670 T DK93906670 T DK 93906670T DK 93906670 T DK93906670 T DK 93906670T DK 0633893 T3 DK0633893 T3 DK 0633893T3
Authority
DK
Denmark
Prior art keywords
carbon atoms
beta
hydrogen atom
pyridyl
alkyl
Prior art date
Application number
DK93906670T
Other languages
English (en)
Inventor
Susan Elaine Barrie
Michael Jarman
Gerard Andrew Potter
Original Assignee
Btg Int Ltd
British Tech Group
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26300621&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0633893(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB929207057A external-priority patent/GB9207057D0/en
Priority claimed from GB929224880A external-priority patent/GB9224880D0/en
Application filed by Btg Int Ltd, British Tech Group filed Critical Btg Int Ltd
Application granted granted Critical
Publication of DK0633893T3 publication Critical patent/DK0633893T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK93906670T 1992-03-31 1993-03-15 17-Substituerede steroider, der er nyttige ved cancerbehandling DK0633893T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929207057A GB9207057D0 (en) 1992-03-31 1992-03-31 Steroids
GB929224880A GB9224880D0 (en) 1992-11-27 1992-11-27 Steroids
PCT/GB1993/000531 WO1993020097A1 (en) 1992-03-31 1993-03-15 17-substituted steroids useful in cancer treatment

Publications (1)

Publication Number Publication Date
DK0633893T3 true DK0633893T3 (da) 2000-04-17

Family

ID=26300621

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93906670T DK0633893T3 (da) 1992-03-31 1993-03-15 17-Substituerede steroider, der er nyttige ved cancerbehandling

Country Status (16)

Country Link
EP (1) EP0633893B1 (da)
JP (1) JP2742331B2 (da)
KR (1) KR100235135B1 (da)
AT (1) ATE186913T1 (da)
AU (1) AU668144B2 (da)
CA (1) CA2132449C (da)
CZ (1) CZ287434B6 (da)
DE (2) DE69327096T2 (da)
DK (1) DK0633893T3 (da)
ES (1) ES2138618T3 (da)
GB (1) GB2265624B (da)
IL (1) IL105078A (da)
LU (1) LU91911I2 (da)
MX (1) MX9301525A (da)
NZ (1) NZ249911A (da)
WO (1) WO1993020097A1 (da)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3722835B2 (ja) * 1993-09-30 2005-11-30 ブリテイツシユ・テクノロジー・グループ・リミテツド １７−（３−ピリジル）ステロイドの合成
DE69417248T2 (de) * 1993-10-27 1999-08-19 Merrell Pharma Inc Delta 16 ungesättigtes c17 heterocyclische steroide zur verwendung als steroid c17-20 lyase inhibitoren
SI1334106T1 (sl) 2000-11-17 2006-10-31 Takeda Pharmaceutical Imidazolni derivati, njihov proizvodni postopek in njihova uporaba
US6960586B2 (en) 2000-11-20 2005-11-01 Takeda Pharmaceutical Company Limited Imidazole derivatives, process for their preparation and their use
CA2431171A1 (en) 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
CA2470214A1 (en) * 2001-12-13 2003-06-26 Abbott Laboratories 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
EP2298316A1 (en) * 2002-08-28 2011-03-23 Harbor BioSciences, Inc. Therapeutic treatment methods
JP5199667B2 (ja) * 2004-08-24 2013-05-15 ビーティージー・インターナショナル・リミテッド 中間体としての１７−ｏ−ビニル−トリフレートの調製のための方法
GB0418900D0 (en) 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
US20100047338A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
DE102006008074B4 (de) * 2006-02-22 2013-08-14 RUHR-UNIVERSITäT BOCHUM Behandlung von Krebs mit Geruchsrezeptor-Liganden
EP3804730A1 (en) 2006-08-25 2021-04-14 Janssen Oncology, Inc. Compositions for treating cancer
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
CN102686600A (zh) * 2009-02-05 2012-09-19 托凯药业股份有限公司 甾体cyp17抑制剂/抗雄激素物质的新型药物前体
JO2892B1 (en) 2009-06-26 2015-09-15 نوفارتيس ايه جي CYP inhibitors 17
US20120282331A1 (en) * 2009-11-13 2012-11-08 Tokai Pharmaceuticals, Inc. Mammalian metabolites of steroids
WO2011088160A2 (en) * 2010-01-15 2011-07-21 Biomarin Pharmaceutical Inc. Novel cyp17 inhibitors
WO2012018948A2 (en) 2010-08-04 2012-02-09 Pellficure Pharmaceuticals, Inc. Novel treatment of prostate carcinoma
US8946260B2 (en) 2010-09-16 2015-02-03 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
CN102558274B (zh) * 2010-12-08 2014-10-15 深圳万乐药业有限公司 一种适合工业化生产醋酸阿比特龙的合成方法
WO2012083112A2 (en) * 2010-12-16 2012-06-21 Biomarin Pharmaceutical Inc. Cyp11b, cyp17, and/or cyp21 inhibitors
CN102558275A (zh) * 2010-12-20 2012-07-11 天津药物研究院 α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物
US9029399B2 (en) 2011-04-28 2015-05-12 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
DE102011083725A1 (de) * 2011-09-29 2013-04-04 Bayer Pharma AG Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
CN102321142A (zh) * 2011-09-29 2012-01-18 重庆医药工业研究院有限责任公司 一种醋酸阿比特龙晶型及其制备方法
BR112014008671B1 (pt) * 2011-10-10 2022-07-12 Zach System Processos de preparação de abiraterona e de acetato de abiraterona, e, composto intermediário
CN103059090B (zh) * 2011-10-20 2016-06-22 连云港润众制药有限公司 醋酸阿比特龙草酸盐以及醋酸阿比特龙的纯化方法
DK2785349T4 (da) 2011-11-30 2023-01-09 Astrazeneca Ab Kombinationsbehandling af cancer
EP2607371A1 (en) 2011-12-23 2013-06-26 Crystal Pharma, S.A.U. Processes for the preparation of abiraterone and related compouds
CN103172690B (zh) * 2011-12-23 2016-08-24 重庆医药工业研究院有限责任公司 醋酸阿比特龙及其中间体的制备方法
CN105461777B (zh) * 2012-01-04 2017-07-18 连云港润众制药有限公司 一种醋酸阿比特龙的纯化方法
CN103254265B (zh) 2012-02-21 2016-07-13 上海希迈医药科技有限公司 醋酸阿比特龙三氟乙酸盐及其制备方法和应用
CN102627681B (zh) * 2012-03-23 2016-04-13 山东新时代药业有限公司 一种醋酸阿比特龙的制备方法
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
WO2013159225A1 (en) * 2012-04-23 2013-10-31 Alphora Research Inc. Process for preparation of 17-substituted steroids
BR112014030099A2 (pt) 2012-06-06 2017-06-27 Novartis Ag combinação de um inibidor 17-alfa-hidroxilase(c17,20-liase) e um inibidor pi-3 k específico para tratamento de uma doença de tumor
CN102731605B (zh) * 2012-06-19 2016-04-13 鲁南制药集团股份有限公司 一种醋酸阿比特龙的纯化方法
PE20150353A1 (es) * 2012-07-10 2015-03-28 Bayer Pharma AG Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos
WO2014009436A1 (en) 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
WO2014009434A1 (en) 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
WO2014009437A1 (en) 2012-07-11 2014-01-16 Sandoz Ag Oxidation stability of abiraterone acetate
WO2014016830A1 (en) * 2012-07-25 2014-01-30 Mapi Pharma Ltd. Process and intermediates for the preparation of abiraterone acetate
WO2014058785A1 (en) 2012-10-10 2014-04-17 Novartis Ag Combination therapy
ITMI20121788A1 (it) 2012-10-22 2014-04-23 Olon Spa Procedimento per la purificazione di abiraterone acetato
EP2917226A1 (en) 2012-11-09 2015-09-16 Synthon BV Process for making the 17-triflate intermediate of abiraterone-3-acetate
EP2917225A1 (en) 2012-11-09 2015-09-16 Synthon BV Process for making abiraterone-3-acetate
TWI570131B (zh) * 2012-11-13 2017-02-11 賽克系統公司 製備１７－經取代類固醇之方法
WO2014075978A1 (en) 2012-11-16 2014-05-22 Synthon B.V. Process for the production of abiraterone-3-acetate involving an enol trliflation reaction in the presence of an alkoxy-pyridine compound
CN103059091B (zh) * 2012-11-22 2017-04-19 常州靶点医药科技有限公司 一种避免重金属残留的醋酸阿比特龙的制备方法
CN103864878A (zh) * 2012-12-12 2014-06-18 天津大学 阿比特龙醋酸酯的制备方法
WO2014102833A2 (en) 2012-12-31 2014-07-03 Hetero Research Foundation Process for abiraterone acetate
EP2968219B1 (en) 2013-03-14 2019-04-24 Pellficure Pharmaceuticals, Inc. Novel therapy for prostate carcinoma
EP2968370A4 (en) 2013-03-14 2016-09-21 Univ Maryland AGENT FOR ANDROGEN RECEPTOR DOWNWARD CONTROL AND USES THEREOF
RS55673B1 (sr) 2013-04-19 2017-06-30 Zach System Postupak za dobijanje čvrstog oblika abirateron acetata
IN2013MU02133A (da) * 2013-06-24 2015-06-05 Sun Pharmaceutical Ind Ltd
WO2015014686A1 (en) 2013-07-29 2015-02-05 Industriale Chimica S.R.L. Process for the preparation of abiraterone or abiraterone acetate
ES2663469T3 (es) 2013-07-29 2018-04-12 Industriale Chimica S.R.L. Proceso para la preparación de abiraterona y acetato de abiraterona
ITMI20131861A1 (it) * 2013-11-08 2015-05-09 Ind Chimica Srl Processo per la preparazione di abiraterone e abiraterone acetato
JP2016528252A (ja) 2013-08-12 2016-09-15 トーカイ ファーマシューティカルズ， インコーポレイテッド アンドロゲン標的治療を使用する新生物障害の処置のためのバイオマーカー
CN104558091B (zh) * 2013-10-16 2017-07-28 天津金耀集团有限公司 一种醋酸阿比特龙的合成方法
WO2015114518A2 (en) * 2014-01-28 2015-08-06 Olon S.P.A. Procedure for the preparation of abiraterone acetate and intermediates thereof
CN103965282B (zh) 2014-04-21 2016-01-20 武汉百科药物开发有限公司 一种醋酸阿比特龙的制备方法
US9315541B2 (en) 2014-05-20 2016-04-19 Olon S.P.A. Process for the preparation of unsaturated trifluoromethanesulfonate steroid derivatives
WO2016001208A1 (en) 2014-06-30 2016-01-07 Galenicum Health S.L. Stable pharmaceutical compositions in the form of immediate release tablets
CZ2014475A3 (cs) 2014-07-09 2016-01-20 Zentiva, K.S. Způsob přípravy Abirateron acetátu o vysoké čistotě aplikovatelný v průmyslovém měřítku
CA2960750A1 (en) 2014-09-12 2016-03-17 Pellficure Pharmaceuticals, Inc. Compositions and methods for treatment of prostate carcinoma
CA2969675C (en) 2014-12-05 2023-06-06 Aragon Pharmaceuticals, Inc. Anticancer compositions
EP3280448B1 (en) 2015-04-10 2020-12-30 Capsugel Belgium NV Abiraterone acetate lipid formulations
EP3392261B1 (en) * 2016-02-02 2021-03-31 Shenzhen TargetRx, Inc. Steroidal compound, composition containing the same and use thereof
MX2018014846A (es) 2016-06-03 2019-03-14 Aragon Pharmaceuticals Inc Composiciones antineoplasicas.
MA45780A (fr) 2016-07-29 2019-06-05 Janssen Pharmaceutica Nv Méthodes de traitement du cancer de la prostate
EP3528799A1 (en) 2016-10-24 2019-08-28 Pellficure Pharmaceuticals, Inc. Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione
EP3784218A1 (en) 2018-04-26 2021-03-03 Synthon B.V. Tablet compositions comprising abiraterone acetate
HU231297B1 (hu) 2018-07-31 2022-09-28 Richter Gedeon Nyrt Stabil gyógyszerkészítmények és eljárás az előállításukra
CN110272465A (zh) * 2019-07-15 2019-09-24 成都贝诺科成生物科技有限公司 阿比特龙衍生物、其制备方法与应用
US20210038578A1 (en) 2019-08-08 2021-02-11 Laekna Limited Method of treating cancer
EP3854384A1 (en) 2020-01-27 2021-07-28 Adamed Pharma S.A. Pharmaceutical formulation comprising abiraterone acetate
JP2023524808A (ja) 2020-05-08 2023-06-13 ヤンセン ファーマシューティカ エヌ．ベー． アビラテロン酢酸エステル及びニラパリブの組み合わせでの前立腺癌の治療
EP3944860A1 (en) 2020-07-30 2022-02-02 Galenicum Health S.L.U. Abiraterone for use in a method of treating cancer
WO2023148345A1 (en) 2022-02-04 2023-08-10 Janssen Pharmaceutica Nv Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and hrr alterations
WO2023155846A1 (zh) * 2022-02-18 2023-08-24 上海醇健医药技术有限公司 17-吡啶基-10α-甲基-甾体衍生物及中间体化合物、其制备方法、其用途、以及其药物组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ224288A (en) * 1987-04-22 1989-12-21 Merrell Dow Pharma 17b-(cyclopropylamino)androst-5-en-3b-ol and related compounds and methods using these for treatment of non-humans
US4966898A (en) * 1989-08-15 1990-10-30 Merrell Dow Pharmaceuticals Inc. 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors

Also Published As

Publication number Publication date
DE122012000012I1 (de) 2012-06-14
EP0633893A1 (en) 1995-01-18
CA2132449A1 (en) 1993-10-14
GB2265624B (en) 1995-04-19
AU3758493A (en) 1993-11-08
LU91911I2 (fr) 2012-02-07
AU668144B2 (en) 1996-04-26
EP0633893B1 (en) 1999-11-24
IL105078A0 (en) 1993-07-08
KR100235135B1 (ko) 2000-01-15
IL105078A (en) 1997-11-20
DE69327096D1 (de) 1999-12-30
NZ249911A (en) 1996-06-25
JP2742331B2 (ja) 1998-04-22
KR950700923A (ko) 1995-02-20
CZ287434B6 (en) 2000-11-15
MX9301525A (es) 1994-02-28
ATE186913T1 (de) 1999-12-15
JPH07505377A (ja) 1995-06-15
CZ233794A3 (en) 1995-02-15
DE69327096T2 (de) 2000-06-21
ES2138618T3 (es) 2000-01-16
CA2132449C (en) 2002-09-10
WO1993020097A1 (en) 1993-10-14
GB9305269D0 (en) 1993-05-05
GB2265624A (en) 1993-10-06

Similar Documents

Publication Publication Date Title
DK0633893T3 (da) 17-Substituerede steroider, der er nyttige ved cancerbehandling
RU2210574C2 (ru) Очищенные стероидсульфаматные соединения, эстрон-сульфаматы
KR950701527A (ko) 테스토스테론 5α 환원효소 활성 저해제(INHIBITORS OF TESTOSTERONE 5α-REDUCTASE ACTIVITY)
GR3033524T3 (en) Steroids which inhibit angiogenesis.
KR880012633A (ko) C_17 내지 C_20 리아제 억제제로서 유용한 17β-(사이클로프로필아미노)안드로스트-5-엔-3β-올 및 관련 화합물
DE69205405T2 (de) 17-Spirofuran-3'-Yliden Steroide.
ZA906710B (en) 7-keto or hydroxy 3,5-diene steroids as inhibitors of steroid 5-alpha-reductase
PT88648A (pt) Process for the preparation of new androstane 17-carboxylic acid esters and a pharmaceutical composition containing same
DE2960689D1 (en) Fluorene and fluoranthene derivatives, process for their preparation and their therapeutic application
KR940701260A (ko) 스테로이드 함유 안구용 약제조성물, 이것을 녹내장 치료에 사용하는 방법 및 이것의 제조방법
OA06613A (fr) Nouveaux dérivés d'amino-14 stéroïdes et procédé pour leur préparation.
ES8707518A1 (es) Un procedimiento para preparar nuevos derivados del 1,3-ben-zoxatiol
GB989881A (en) Improvements in or relating to 10 -methyl steroids and the production thereof
CA1266641C (en) 16-keto-17-substituted thia-17-alkyl (or alkenyl or alkynyl) androstenes
GB905845A (en) Steroid compounds and the preparation thereof
HUT42783A (en) Process for preparing steroid aromatase-inhibitors
TW343976B (en) 17-substituted steroids useful in cancer treatment
GB1063663A (en) Improvements in or relating to steroids and the manufacture thereof
WO1990015067A3 (fr) NOUVEAUX PROCEDES D'OBTENTION DE 6-METHYL 19-NOR STEROIDES ET LEUR CONVERSION EN 19-NOR PREGNADIENES 17α-SUBSTITUES
ES403723A2 (es) Un procedimiento para la preparacion de esteroides de la serie del pregnano
GB1089915A (en) Novel 7-alkyl-19-nor-steroids
GB1099008A (en) Novel unsaturated steroids, and processes for their preparation
GB961101A (en) Steroid compounds
ES2037871T3 (es) Procedimiento para preparar 1-metil-androsta-1,4-dieno-3,17-diona y los nuevos productos intermedios para este procedimiento.
GR23003B (el) Μεθοδος δια την παραγωγην ωρισμενων παραγωγων τησσειρας του ανδροστανιου.